Social Behavior
Roche and COUR Pharmaceuticals Collaborate on Autoimmune Disease Treatment in Deal Worth Over $900 Million
Roche, COUR Pharmaceuticals, autoimmune disease, Genentech, antigen-specific immune tolerance platform, biotech collaboration
European Commission Revokes Marketing Authorization for Ocaliva, a Liver Disease Drug, Amid Regulatory Dispute
Ocaliva, European Commission, Marketing Authorization, Liver Disease, Primary Biliary Cholangitis (PBC), Advanz Pharma
Novartis Invests $1 Billion in PTC Therapeutics’ Huntington’s Disease Program
Novartis, PTC Therapeutics, Huntington’s disease, Phase 2 drug, global license agreement, collaboration, upfront payment, milestone payments.
Sarepta Therapeutics and Arrowhead Pharmaceuticals Enter $10 Billion Collaboration for Rare Disease Treatments
Sarepta Therapeutics, Arrowhead Pharmaceuticals, RNAi, Rare Diseases, Genetic Medicine, Collaboration Agreement, Biotech, Pharmaceutical Industry
Trump’s NIH Leadership Plans: From Jay Bhattacharya to a More Traditional Pick?
Trump, NIH, Jay Bhattacharya, Warp Speed, Leadership, Biomedical Research
Pfizer Appoints Chris Boshoff as New Chief Scientific Officer and President of Research & Development
Pfizer, Chris Boshoff, Chief Scientific Officer, President of Research & Development, Mikael Dolsten, Leadership Changes, Oncology, R&D
BeiGene Secures Long-Term Protection for BRUKINSA with Patent Settlement Until 2037
BeiGene, BRUKINSA, patent settlement, MSN Pharmaceuticals, generic competition, market exclusivity, BTK inhibitor, cancer treatment
Angela Hwang Joins Flagship Pioneering as CEO-Partner and CEO of Metaphore Biotechnologies
Angela Hwang, Flagship Pioneering, Metaphore Biotechnologies, Pfizer, Biotechnology, Leadership Appointment
Roche and Flare Therapeutics Launch $1.8B-Plus Cancer Collaboration Targeting Transcription Factors
Roche, Flare Therapeutics, transcription factors, cancer drugs, oncology, biotech collaboration
Pharmaceutical Giants Eli Lilly and Novo Nordisk Face Challenges Despite Strong Sales Growth
Eli Lilly, Novo Nordisk, Q3 2024 financial results, Obesity drugs, Weight loss therapies, Pharmaceutical industry challenges, Market competition, Supply pressures, Pricing issues